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Objective: The objective of this systematic literature
eview was to evaluate the incidences and risks for
dverse events (AEs) associated with oral and paren-
eral corticosteroids. An assessment was performed to
stimate the costs of such AEs.
Methods: A systematic review of literature pub-
lished from 2007 to 2009 was conducted to identify
the incidence rates and risk ratios of corticosteroid-
related AEs. The review protocol was developed ac-
cording to PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) guidelines.
The literature search was expanded to include addi-
tional search terms for psychiatric conditions, infec-
tions, and peptic ulcers. Costs obtained from a sep-
arate narrative literature review were applied to AEs
likely to affect third-party payers in the United
States.
Results: A total of 357 publications were identified
rom the primary (n  323) and secondary (n  34)
searches. Of these, 310 were excluded because they did
not evaluate AEs related to corticosteroids, were an
excluded publication type, or for other reasons. A final
list of 47 studies were used for data extraction. Across
patient populations, the most frequently reported cor-
ticosteroid-associated AEs were psychiatric events, in-
fections, gastric conditions, and fractures. Corticoste-
roid-associated AEs reported to occur at an incidence
30%were sleep disturbances, lipodystrophy, adrenal
suppression, metabolic syndrome, weight gain, and hy-
pertension. Vertebral fractures were reported at an in-
cidence of 21% to 30%. Dose-response relationships
were documented for fractures, acute myocardial in-
farction, hypertension, and peptic ulcer. The costs of
managing AEs that may occur with corticosteroids
can be substantial. The literature reported 1-year
per-patient costs of up to $26,471.80 for nonfatal
Month 2011myocardial infarction, and per-event costs as high as
$18,357.90 for fracture. The findings from the pres-
ent review should be interpreted cautiously due to
several limitations, including the retrospective de-
sign of most of the studies identified, risk for con-
founding due to underlying disease activity or pa-
tient population, and the relatively small number of
studies that reported each AE association. As this
cost analysis was preliminary, a comprehensive
pharmacoeconomic analysis should be undertaken
to confirm the findings.
Conclusion: Based on the findings from this review,
systemic corticosteroids are a common cause of AEs
that may be costly to payers. (Clin Ther. 2011;xx:xxx)
© 2011 Elsevier HS Journals, Inc. All rights reserved.
Key words: adverse events, corticosteroids, cost
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INTRODUCTION
Corticosteroids are important and commonly used med-
ications because of their potent anti-inflammatory and
immunosuppressive properties. Systemic corticosteroids
are a mainstay of treatment for many conditions, includ-
ing rheumatologic conditions (eg, rheumatoid arthritis,
temporal arteritis, polymyalgia rheumatica, systemic lu-
pus erythematosus [SLE]), allergic reactions, hepatitis,
obstructive lung diseases (eg, asthma, chronic obstructive
pulmonary disease), and inflammatory bowel diseases
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Clinical Therapeutics(eg, ulcerative colitis, Crohn’s disease).1,2 Systemic corti-
osteroids are also widely used as a part of the immuno-
uppressive regimen after organ transplantation and in
ncology as a part of chemotherapy.2 In 2003–2004, cor-
ticosteroidswere the 19thmost commonlymentioned (ie,
ordered, supplied, administered, or continued) class of
drug at ambulatory care visits, used by an estimated
141.7 per 1000 persons in the United States.3 Prednisone
as the 15th most commonly mentioned drug in US am-
ulatory care visits, with 16.6 millionmentions, or1%
f all mentions of drugs.3 Corticosteroids have dose-re-
lated anti-inflammatory and immunomodulatory effects
that are mediated primarily by genomic mechanisms ac-
Table I. Relationship between clinical dosing and cel
Dosage* Clinical Application
Low (7.5 mg/d) Maintenance
therapy for many
rheumatic diseases
Intermediate (7.5–40
mg/d)
Initial treatment for
primary chronic
rheumatic diseases
High (30–100 mg/d) Initial treatment for
subacute rheumatic
diseases
Very high (100 mg/d) Initial treatment for
acute and/or
potentially life-
threatening
exacerbations of
rheumatic diseases
Pulse therapy (250 mg for
1–3 d)
For particularly
severe and/or
potentially life-
threatening forms
of rheumatic
diseases
Reprinted and adapted with permission from John Wiley an
*Values are prednisone equivalent (mg/d).tivated by corticosteroid binding to glucocorticoid recep-
2tors.4 The direct relationship between corticosteroid dos-
ge and degree of glucocorticoid receptor saturation is
hought to explain the observation that clinical activity
enerally increases with increasing corticosteroid dosage
Table I).4 Likewise, the nonspecific nongenomic activity
of corticosteroids appears to play an increasing role in the
therapeutic effect as dosage increases.4
Although corticosteroids are effective anti-inflam-
matory and immunomodulatory agents, they exact a
toll with respect to adverse events (AEs) and toxicities.
Corticosteroids have been associated with AEs that are
common and may be severe or life-threatening. Ac-
cording to data from the Healthcare Cost and Utiliza-
actions of corticosteroids in rheumatic diseases.
Genomic
Actions
Receptor
uration), %
Nongenomic Actions
Nonspecific
Cytosolic
Glucocorticosteroid
Receptor Mediated
50 Not relevant Unknown
50–100 Perhaps
relevant but
of minor
importance
Perhaps relevant but
of minor
importance
lmost 100 Relevant Relevant
lmost 100 Very relevant Relevant or perhaps
even very relevant
100 Most
relevant
Relevant or perhaps
even very or most
relevant
s.4lular
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E. Sarnes et al.common specific cause of drug-related AEs, account-
ing for 10.3% of all drug-related AEs and 141,000
hospital stays in the United States in 2004. The contri-
bution of corticosteroids to morbidity is illustrated by
findings in patients with SLE, who may be prescribed
long-term corticosteroids. In the Hopkins Lupus Co-
hort Study (n  539),5 the cumulative dose of predni-
sone was associated with osteoporotic fractures (rela-
tive risk [RR]  2.5), symptomatic coronary artery
disease (CAD) (RR  1.7), and cataracts (RR  1.9).
Each 2-month period of exposure to high-dose pred-
nisone (defined as 60 mg/d for 2 months) was
associated with a 1.2-fold increase in the risks for
avascular necrosis and stroke. In a study based on a
review of medical records from 11,359 clinic visits in
310 patients with SLE at the Montreal General Hos-
pital, Montreal, Quebec, Canada, the past-year cor-
ticosteroid dose was found to be a predictor of the
2-year risk for CAD, and the 8 risk factors for CAD.6
Although the product costs of corticosteroids are
relatively low, their total direct and indirect costs may
be considerably higher than the price of the drugs
themselves when the cost of managing short- and long-
term AEs is considered. The cost of corticosteroid-as-
sociated AEs has been evaluated in few studies, each
having limited representativeness or generalizability
with respect to factors such as patient population and
country (ie, variability in currency, costs of medical
services, and treatment patterns).7,8 Information on
he costs of corticosteroid-associated AEs is important
o physicians and payers in evaluating treatment strat-
gies for conditions for which corticosteroids are pre-
cribed. The present investigation evaluated the inci-
ences of and risks for AEs associated with oral and
arenteral corticosteroids in the general population,
sing a systematic review of interventional and obser-
ational studies published in the medical literature. A
arrative review was used for determining the costs of
he AEs likely to affect third-party payers in the United
tates.
METHODS
The present study was an extension and amplification
of a review of the medical literature published from
1990 to 20077 of the costs attributable to corticoste-
oid-associated AEs based on population rates and
osts in the United Kingdom, conducted by Manson
t al.7 Although that study reviewed costs in the United
Kingdom, it was chosen as a foundation for this US-
Month 2011focused initiative because of its recency and its compre-
hensiveness relative to other assessments of corticoste-
roid-associated AEs.
The latter review identified 21 categories of oral
corticosteroid-related AEs and reported, based on an
analysis of selected AEs, that the cost of treating
these events in the United Kingdom was at least £165
per patient per year (US $344 [2009 US dollars]).
The present study extended the time frame for litera-
ture analysis toOctober 2009 and included searches on
specific AEs.
Publications on corticosteroid-associated AEs were
identified using a literature-search strategy developed
to complement the methods ofManson et al.7 A search
protocol was developed a priori, following PRISMA
(Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) guidelines. A brief summary of the
search strategy is shown in Table II. Included were
publications based on clinical trials, observational
studies, reviews (for the purposes of identifying poten-
tial studies rather than for data extraction), or eco-
nomic evaluations reporting AEs or tolerability pro-
files of systemic corticosteroids.
Non–English-language publications were excluded,
as were publications on inhaled or intranasal topical
corticosteroids, which may have lacked significant sys-
temic absorption. Initially, publications appearing be-
tween April 2007 and October 2009 were eligible for
inclusion; however, because some commonly reported
AEs were not captured using those date limits, a sec-
ondary search was conducted to identify literature on
psychiatric conditions, infections, and peptic ulcers.
The second search was not limited to the 2007–2009
time period and was based on citations from other
systematic reviews. Both searches were completed in
March 2010.
One reviewer (E.S.) used the titles and abstracts
identified in the initial literature search to identify po-
tentially relevant publications, the full-text versions of
which were retrieved. Study characteristics including
design, patient characteristics, corticosteroid charac-
teristics, and incidences and risk ratios of reported AEs
were extracted and summarized on a standardized
form for the included publications. To evaluate dose-
response relationships, all corticosteroid dosages were
converted to prednisolone-equivalent daily doses.
Using criteria previously used by Manson et al,7,9
the quality of original research publications was eval-
uated with respect to patient selection, description/
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Clinical Therapeuticsspecification of the interventions, specification and
analysis of the study, patient disposition, and outcomes.
Each of the 5 criteria was graded on a scale of 0 to 2 (0
information not available or criteria not met; 1  par-
ially described or partially met criteria; and 2  fully
described or criteria fullymet), and scores for the individ-
ual criteria were summed to arrive at a total quality score
ranging from 0 to 10. Based on the total quality score,
studies were deemed to be high quality (score, 9 or 10),
good quality (7 or 8), fair to good quality (5 or 6), poor to
fair quality (3 or 4), or poor quality (1 or 2).9 Studies that
ere poor to fair (4) were excluded from the analysis.
eta-analyses and abstracts (n  5 publications) were
Table II. Summary of the methods and strategies use
and US costs of corticosteroid-associated a
Method
Databases MEDLINE (via PubM
2007–October 2009
presented at therape
lists of systematic an
(2007–2009); intern
National Institute fo
Service Economic Ev
Search terms MeSH terms: glucocor
specific terms: betam
hydrocortisone, methylp
general terms for AE
specific terms for AE
(BMD), hypocalcemia,
suppression, adrenocort
cardiovascular, hyperten
neuropsychiatric, psycho
immunosuppression, ca
effects, non-Hodgkin’s l
Publication inclusion criteria Publications that rep
corticosteroids; stud
economic evaluation
corticosteroids (ie, o
specific agents)
Publication exclusion criteria Non-English languag
reporting non–cortic
corticosteroids (becl
inhaled corticosteroixcluded from this quality evaluation.
4Cost Analysis
A cost analysis was undertaken to determine the eco-
nomic burden of corticosteroid-induced AEs. Clinically
relevantAEs considered likely to affect third-party payers
in the United States were identified from the literature
review. Because of the paucity of literature on US-only
costs, the cost assessment was not restricted to US costs.
AEs that were not directly related to a clinical event (eg,
reduced bone mineral density) were excluded, as were
AEs that were deemed to require only over-the-counter
treatment or to be self-limiting.
A separate narrative literature search was under-
taken to identify the costs of events that were identified
the literature search in this analysis of the incidence
e events (AEs).
Strategy
April 1, 2007–October 31, 2009; EMBASE, April
hrane Library, April 2007–October 2009; abstracts
onferences the past 2 years (2007–2009); citation
systematic reviews, health technology assessments
s of Agency for Healthcare Research and Quality,
lth and Clinical Excellence, and National Health
ion Database
s, pregnadienetriols, corticosteroid, and steroid (general);
ne, budesonide, cortisone, dexamathasone, fludrocortisones,
olone, prednisolone, prednisone, and triamcinolone;
effect, adverse event, adverse effect, safety, and tolerability;
oporosis, fracture, osteopenia, bone mineral density
rine, diabetes, hyperglycemia, obesity, weight gain, adrenal
sufficiency, Cushingoid, growth retardation/suppression,
myocardial infarction/heart attack, stroke, atherosclerosis,
ania, anxiety, depression, insomnia, infection,
sis/candidemia, wound healing, cataracts, glaucoma, ocular
ma, acne, and peptic ulcer
AEs or tolerability profiles of systemic
s: clinical trials, observational studies, or reviews;
rugs, treatments, or therapy; interventions; systemic
parenteral route) (see search terms for list of
sertations or editorials, case reports, publications
oid-specific AEs, interventions, inhaled or intranasal
hasone, flunisolide, fluticasone, mometasone),
opulations infants (1 year)d for
dvers
ed),
; Coc
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E. Sarnes et al.that search provided estimates of an event that would
be anticipated to occur regardless of causality. These
cost estimates were applied to the RR of the event oc-
curring with corticosteroid therapy to derive the cost
attributable to corticosteroids. This basic modeling
approach was undertaken because no studies were
identified that evaluated the incidences and costs of
AEs directly attributable to corticosteroids.
To examine the potential reduction in economic
burden achievable by reducing corticosteroid daily
dose, a cost analysis was conducted on the AEs with
the most clear dose-response relationship identified in
the review: myocardial infarction (2 studies)46,54 and
fracture (8 studies).19,25,44–46,49,51,54 The cost analy-
is evaluated the costs of AEs occurring with high
aily doses versus low daily doses of corticosteroids
ased on the published literature. One of the limita-
ions of this cost-analysis approach was the potential
o overestimate or underestimate the actual costs of
Es. The published literature contains “cost” esti-
ates, which may have included billed charges, ne-
otiated payments or reimbursed amounts, or actual
osts to the provider or system. Studies that pre-
ented charged amounts as the cost of an event may
ave overestimated the true cost to the provider or
ystem. When possible, the actual costs of care were
etermined. However, many pharmacoeconomic
tudies used paid amounts based on published pro-
essional fee schedules or publicly available payment
chedules (eg, Medicare Prospective Payment Sys-
ems) to estimate costs.
RESULTS
Study Disposition and Characteristics
The Figure shows the disposition of publications
dentified for the analysis. The number of unique, po-
entially relevant publications identified and screened
or retrieval was 323, of which 47 (27 from the pri-
ary search, 20 from the secondary search) were in-
luded in the data extraction.10–56 More than half of
he 47 studies described in the publications were retro-
pective analyses (30 case–control studies, 10 cross-
ectional studies, and 8 cohort studies). Twenty-one of
he studies were conducted in Europe; United States,
3; Asia, 7; and other, 6. Of the 42 studies evaluated
or quality, 9 were of high quality, 26 were of good
uality, and 3 were of fair to good quality. A total of 4
tudies were excluded from the analysis of AEs because
f poor quality.13,18,26,36
Month 2011One study was conducted in patients with acute
conditions (acute optic neuritis); 26 were conducted in
patients with chronic conditions; and 16 were con-
ducted in the general population. Rheumatoid arthritis
was the most commonly studied condition (7 publica-
tions) followed by acute lymphoblastic leukemia,
asthma, SLE, pulmonary diseases, and nonspecified
rheumatic disease (2 publications each). Twenty-four
studies evaluated oral corticosteroid use only; the re-
maining 19 studies included parenteral administration
or parenteral and/or oral administration. In the 18
studies in adults,38% of patients were male, and the
mean age was 56 years. The number of studies in-
olving pediatric patients only was 6. A summary of
he studies included in the analysis of corticosteroid-
elated AEs is shown in Table III.
Corticosteroid-Associated Adverse Events
The mechanisms by which corticosteroids induce
undesired effects are complex and varied. The immu-
nosuppressive and anti-inflammatory properties of
corticosteroids, which are the primary source of their
therapeutic value, are also the cause of untoward AEs,
including an increased risk for infections.57 On a mo-
ecular level, many of the other AEs are related to their
ffects on the endocrine system, electrolyte balance,
nd metabolism. Corticosteroids cause adrenal sup-
ression through negative feedback of the hypothala-
us, anterior pituitary, and adrenal gland.57 The re-
sulting adrenal suppression results in many of the
commonly known AEs, such as Cushing’s syndrome,
adrenal insufficiency, and growth inhibition. In addi-
tion, reduced concentrations of adrenal hormones may
play a role in the development of osteoporosis and
neuropsychiatric disorders. Corticosteroids also cause
electrolyte and fluid imbalance, including increased so-
dium reabsorption in the kidneys, increased urinary
excretion of potassium and calcium, and decreased cal-
cium gut absorption.58 The resulting sodium retention
and hypokalemia may cause elevated blood pressure
(hypertension) and edema; the decreased calcium
stores in the body contribute to the development of
bone loss and fracture risk.57–59 Bone formation is also
educed due to the inhibitory effects of corticosteroids
n osteoblast activity.59 Corticosteroids simulate glu-
ose production by activating enzymes of gluconeo-
enesis; the result is an increased risk for hyperglyce-
ia, new-onset diabetes, and cataracts.57,58 Theircatabolic activity includes increased inhibition of glu-
5
Clinical Therapeuticscose utilization in peripheral tissue and skeletal muscle
protein breakdown (which can lead to muscle myopa-
thy). Direct effects of corticosteroids that may result in
AEs include increased gastric acid secretion (potential
increased risk for ulcers), increased cardiac fibrosis
(potential increased risk for myocardial infarction and
other cardiovascular conditions), and neuronal
Figure. Disposition of publications identified in the lit
case study or series (n  50), or that the stu
events (AEs) without describing the incidenc
that the study evaluated the effects of cortico
in patient populations but did not specify corchanges (potential for psychiatric disorders).57,58
6Awide variety of corticosteroid-associated AEs was
reported across patient populations. In the 27 studies
identified from the primary literature search, the most
frequently reported AEs (assessed as the number of
unique times a specific AE was reported in the publica-
tions) were psychiatric events (6 reports), fractures (4),
and cancer (1 each of malignant melanoma, squamous
re search. *The main miscellaneous reasons included
aluated therapies to alleviate corticosteroid adverse
Es (n  13). Other miscellaneous reasons included
ids in animal models or cell models or evaluated AEs
teroid use.eratu
dy ev
e of A
stero
ticoscell carcinoma, basal cell carcinoma, and non-Hodg-
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Table III. Summary of studies identifying adverse events (AEs) associated with corticosteroids based on data from the published literature in this
analysis of the incidence and US costs of corticosteroid-associated AEs.
Study Study Design
Quality
Score*
Corticosteroid
Studied Reported AEs
Akerkar et al (1997)10 Cross-sectional study in 115 patients with
Crohn’s disease
7 Hydrocortisone Hypertension, mental status change, hypokalemia, hyperglycemia,
nosocomial infection, congestive heart failure
Avina-Zubieta et al (2009)11 Retrospective cohort study of data from
6981 patients with rheumatoid arthritis
n/a Any Myocardial infarction
Bolanos et al (2004)12 Prospective cohort study in 34 patients
with asthma or rheumatic disease
8 PD 7.5 mg/d for 6 mo Mania/hypomania, depression
Boston Collaborative Drug
Surveillance Program (1972)13
Cross-sectional study in 676 hospitalized
inpatients
4 PD Psychosis/inappropriate euphoria, GI reactions,
hyperglycemia/diabetes, infection
Brown et al (2002)14 Prospective cohort study in 32 patients
with asthma
7 PD for 7 d Mood disturbances
Christiansen et al (2009)15 Case–control study in 20,221 patients and
controls
8 PD, MP, DEX,
hydrocortisone
Hospitalization for atrial fibrillation or flutter
Chrousos et al (1993)16 Randomized controlled trial in 457
patients with acute optic neuritis
7 MP 1 g/d for 3 d
PD 1 mg/kg for 11 d
or PD 1 mg/kg for
14 d then tapered
Sleep disturbance, mood disturbances, stomach upset
Conn and Poynard (1994)17 Meta-analysis of data from 6602 patients n/a Any Peptic ulcers (new or exacerbated), bacterial sepsis, tuberculosis,
diabetes, osteoporosis, hypertension, psychosis
Da Silva and Schiff (2007)18 Cross-sectional study in 5 patients
receiving neuro-oncologic care
2 Any Secondary adrenal insufficiency
de Vries et al (2007)19 Retrospective cohort study of data from
191,752 patients
9 Any Fractures (any, hip/femur fracture, vertebral fracture)
Dietrich et al (2009)20 Case–control study in 786 patients and
controls
7 Any Bladder cancer
Dowell and Bresee (1993)21 Case–control study in 35 patients and
controls
6 Any Varicella infection
Einaudi et al (2008)22 Randomized controlled trial in 64 patients
with acute lymphoblastic leukemia
7 PD 60 mg/m2/d or
DEX 10 mg/m2/d for
30 d
Severe adrenal suppression, severe infection and adrenal
suppression
Fardet et al (2007)23 Prospective cohort study in 88 patients
with chronic disorders
9 Any, 20 mg/d for
3 mo
Lipodystrophy
Fardet et al (2007)24 Prospective cohort study in 88 patients
with chronic disorders
9 Any, 20 mg/d for
3 mo
Lipodystrophy, hypertension, hirsutism, spontaneous bruising,
altered wound healing, swollen ankles, hand tremors, muscle
cramps, proximal muscle weakness, insomnia, neuropsychiatric
disorders, irritability, anxiety/depression, euphoria/hyperactivity,
manic episode, epigastric pain, hyperphagia
Gabriel et al (1997)25 Cross-sectional study in 232 patients with
rheumatic polymyalgia
7 Any Diabetes, fractures (vertebral fracture, Colles’ fracture, hip/femur
fracture, femoral neck fracture), aseptic necrosis, cataracts,
infection, GI bleed, hypertension, myopathy
(continued)
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Table III (continued).
Study Study Design
Quality
Score*
Corticosteroid
Studied Reported AEs
Garcia-Berrocal et al (2008)26 Retrospective cohort study of data from
163 patients with sudden sensorineural
hearing loss
4 MP 1 mg/kg/d
tapered over 21–28 d
Cushingoid features, muscle weakness, hyperglycemia, reduction in
libido, insomnia, vertigo, otorrhea, perforation of the tympanic
membrane, peptic ulcer, osteonecrosis of femoral head
Greenberg et al (2007)27 Prospective cohort study in 11,429
patients with rheumatoid arthritis
n/a PD Infection
Hafstrom et al (2007)28 Subanalysis of randomized controlled trial
in 67 patients with early-onset rheumatoid
arthritis
10 PSL 7.5 mg/d for
2 y
Carotid atherosclerosis, endothelial function
Hernandez-Diaz and Rodriguez
(2001)29
Nested case–control study in 2105 patients
and controls
8 Any Upper GI complications including gastric or duodenal damage,
gastric or duodenal lesions, GI bleed, or perforated ulcer
Huscher et al (2009)30 Cross-sectional study in 1066 patients with
rheumatoid arthritis
8 Any, 6 mo Cushingoid phenotype, ecchymosis, leg edema, mycosis,
parchmentlike skin, shortness of breath, sleep disturbance,
cataracts, depression/listlessness, glaucoma, elevated BP, epistaxis,
weight gain
Jensen et al (2009)31 Case–control study in 7821 patients and
controls
9 Any Non-Hodgkin’s lymphoma, squamous cell carcinoma, basal cell
carcinoma, malignant melanoma
Jick et al (2006)32 Case–control study in 497 patients and
controls
9 Any Tuberculosis
Kameda et al (2009)33 Prospective cohort study in 44 patients
with rheumatic disease
7 Any, 0.5 mg/kg Vertebral fracture, osteonecrosis of femoral head
Luo et al (2009)34 Prospective paired study in 67 patients in
systemic lupus erythematosus
8 MP 1 g/d for 2 d, with
2-wk intervals
Gastric mucosal injury
Messer et al (1983)35 Meta-analysis of data from 3064 patients n/a Any, for4 d Ulcers, GI hemorrhage
Naber et al (1996)36 Prospective cohort study in 50 patients
with ocular disease
4 MP, fluocortolone
150 mg/d for 8 d
then tapered
Hypomanic syndrome, depressive syndrome
Nerome et al (2008)37 Cross-sectional study in 34 patients with
rheumatic diseases
6 PSL, MP Cataracts
Ng et al (2009)38 Retrospective cohort study of data from 45
patients with myeloma
5 DEX 40 mg for 4 d,
then 4 d off for 28-d
cycle
Adrenal suppression
Nishimura et al (2008)39 Prospective cohort study in 135 patients
with systemic lupus erythematosus
7 PSL Psychiatric disorders
Panoulas et al (2008)40 Cross-sectional study in 400 patients with
rheumatoid arthritis
7 PSL 6 mo Hypertension
Patel et al (1996)41 Case–control study in 167 patients and
controls
7 PD, hydrocortisone Varicella infection
(continued)
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Table III (continued).
Study Study Design
Quality
Score*
Corticosteroid
Studied Reported AEs
Piper et al (1991)42 Nested case–control study in 1415 patients
and controls
8 Any Peptic ulcer
Te Poele et al (2007)43 Cross-sectional study in 1289 patients with
acute lymphoblastic leukemia
7 DEX 6 mg/m2/d for
14 d every 14 wk for
1 y
Death from infection
Proven et al (2003)44 Retrospective cohort study of data from
120 patients with giant cell arteritis
7 Any Diabetes mellitus, fracture (hip/femur fracture, vertebral fracture,
Colles’ fracture, other fractures), GI bleeding, hypertension,
infection, cataracts
Reyes et al (2007)45 Prospective cohort study in 55 patients 8 Any, for6 mo Vertebral fracture
Saag et al (1994)46 Retrospective cohort study of data from
112 patients with rheumatoid arthritis
8 Any, 1 y Fracture, serious infection, GI bleed or ulcer, cataracts, diabetes,
herpes zoster, myocardial infarction, stroke, glaucoma, death
Shibatani et al (2008)47 Cross-sectional study in 150 patients
undergoing renal transplant
7 MP 500 mg or PSL 50
mg during surgery,
then PSL 50 mg for
3–7 d for 6 wk, then
10 mg/d maintenance
Osteonecrosis of femoral head
Smyllie and Connolly (1968)48 Retrospective cohort study of data from
550 patients with respiratory disease
7 Any, for1 mo Diabetes, peptic ulcer, GI bleeding/hemorrhage, perforated ulcer,
mental disturbance, collapsed vertebra, sudden death, obesity,
hypertension
Sosa et al (2008)49 Cross-sectional study in 88
postmenopausal women
9 Any, 7.5 mg/d for
6 mo
Vertebral fracture
Stuck et al (1989)50 Meta-analysis of data from 2111 patients n/a Any Infectious complications
Sugiyama et al (2009)51 Retrospective cohort study of data from
700 patients with collagen vascular
diseases
7 Any, 20 mg/d for
6 mo
Vertebral fracture
Toms et al (2008)52 Cross-sectional study in 117 patients with
rheumatoid arthritis
8 PSL Metabolic syndrome
Uzu et al (2007)53 Prospective cohort study in 42 patients
with primary renal disease
7 PSL, MP 30–40 mg/d
for 4 wk
Diabetes
Varas-Lorenzo et al (2007)54 Nested case–control study in 4795 patients
and controls
9 Any Acute myocardial infarction
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1kin’s lymphoma in 1 study). In the 43 studies included,
the most frequently reported AEs were psychiatric events
(16 reports), infections (14), gastric conditions (12), and
fracture/increased risk for fracture (11).*When only AEs
that were reported to be significantly associatedwith cor-
ticosteroids were identified, gastric conditions were the
most frequently reported AEs (11 unique reports), fol-
lowed by infection (9 reports) and psychiatric events (8
reports) (Table IV). Corticosteroid-associated AEs re-
ported in the literature to occur at an incidence of30%
ere sleep disturbances, lipodystrophy, adrenal suppres-
ion, metabolic syndrome, weight gain, and hyperten-
ion. Vertebral fractures were reported at an incidence of
1% to 30%. Corticosteroid-associated AEs reported at
n incidence 10% were severe gastrointestinal AEs
1%–5%), severe infections (0.2%–3.1%), and myocar-
ial infarction (4%).
Table V shows the AEs categorized by risk measure
including hazard ratios [HRs], incidence risk ratios
IRRs], relative risks [RRs], and odds ratios [ORs])
cross patient populations. The time frames over
hich risks were characterized varied among studies.
nly AEswith a significant difference between patients
ho received corticosteroids and those who did not
eceive corticosteroids are listed. AEs having a strong
ssociation with corticosteroid therapy were fractures,
ardiovascular disorders and events, gastrointestinal
isorders and events, and infections.
Many AEs were associated with a dose-response
attern with increasing daily dose. A relationship be-
ween corticosteroid daily dose and the incidence of
ractures was observed across several studies; when
ombined, the estimated risk ratio was 1.0 at daily
oses 7.5 mg and 1.8 at daily doses of 7.5 to 15
g.† In addition, a relationship between corticosteroid
daily dose and the incidence of acute myocardial in-
farction was observed, with estimated risk ratios of
1.26 (95% CI, 1.02–1.57) at daily doses 10 mg and
2.15 (95% CI, 1.45–3.14) at daily doses 10 mg.54 A
relationship between corticosteroid daily dose and the
incidence of peptic ulcer was observed, with estimated
risk ratios of 2.1 (95%CI, 1.4–3.1) at daily doses30
mg and 5.4 (95% CI, 1.9–15.5) at daily doses 30
g.29 Corticosteroids were associated with an in-
creased risk for infection at doses 10 mg/d27,30,50
and, specifically, with an increased risk for tuberculosis
*References 10–12, 14–25, 27–35, and 37–56.
†References 17, 19, 25, 33, 44–46, 49, 51, and 55.
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E. Sarnes et al.at a threshold dose7.5 mg/d.32 The risk for cataracts
ith corticosteroid use was found to be dose related.30
Table IV. Adverse events (AEs) associated with
corticosteroid use based on data from
the published literature in this analysis of
the incidence and US costs of corticoste-
roid-associated AEs.*
AE
No. of Studies That
Reported Significant
Association of 1
Event
Gastric condition 11
Infection 9
Psychiatric events† 8
Fracture 7
Bruising 4
Other‡ 4
Cataracts 3
Diabetes/hyperglycemia 3
Hypertension 3
Muscle
cramps/weakness
2
Myocardial infarction 2
Cancer 2
Lipodystrophy 2
Adrenal suppression 1
Cushingoid features 1
Edema 1
Osteonecrosis of femoral
head
1
Weight gain 1
*Table provides a count of the number of unique times an
AE was reported in the literature. For example, if 2 stud-
ies reported an increased incidence of ulcers associated
with corticosteroid, ulcers were assigned a count of 2.
The number of studies sums to more than 47 studies as
each study may have reported 1 AE. Each AE was
counted only once per study. For example, fracture was
counted only once in a study that reported the preva-
lence of fracture in patients receiving 5 mg/d and in
patients receiving 5 to 7.5 mg/d.
†Psychiatric AEs included anxiety, euphoria/hyperactivity,
mental disturbance, depression, psychosis, mania/hy-
pomania, and mood disorder.
‡Included height loss, hypokalemia, atrial fibrillation/
flutter hospitalization, and parchment-like skin.Other corticosteroid-induced AEs appeared to have a
Month 2011dose-response relationship, but findings from the pub-
lications included in the review were inconsistent.
Cumulative corticosteroid exposure appeared to in-
fluence the risk for certain AEs. Two studies conducted
using data from the Rochester Epidemiology Project
database reported that a higher cumulative dose was a
significant risk factor for any corticosteroid-related AE
(Gabriel et al25: cumulative doses1.8 g, P 0.0092;
Proven et al44: cumulative dose and P not reported).
onsistent with the findings from the review byManson
t al, de Vries et al19 found that the risk for fracture in-
reasedwith cumulative exposure, especially in adults re-
eiving high daily doses (15 mg). As the cumulative
xposure increased from1 to5 g/d in patients receiv-
ng high daily doses, the risk for osteoporotic, hip/femur,
nd vertebral fractures increased substantially, although
he 95% CIs were wide. For example, in patients who
eceived 30 mg/d, the RR of hip/femur fracture was
.13 (95%CI, 1.49–6.59), and the RR of vertebral frac-
ures was 14.42 (95% CI, 8.29–25.08).
Two large meta-analyses included an assessment of
umulative exposure and the risk for peptic ulcers,
ith divergent results.17,35 In a meta-analysis of ran-
omized double-blind trials, Conn and Poynard17 re-
orted that the incidence of peptic ulcers appeared to
ncrease with duration of treatment, although the OR
or the risk for peptic ulcer was not statistically signif-
cant between the corticosteroid and control groups in
hose who received medication for 30 days, 1 to 3
onths, 4 to 12 months, and12 months (mean daily
ose, 35 mg; mean cumulative dose, 2.2 g). In a sepa-
ate analysis of controlled clinical trials, the risk for
eptic ulcer was significantly higher in patients treated
ith corticosteroids for 30 days compared with the
ontrol group (5.0; 95% CI, 1.6–15.8). The risk was
lso significantly elevated in patients who received a
umulative dose of 1.0 g (3.5; 95% CI, 1.5–14.9).35
Other AEs reported to be associated with cumula-
tive corticosteroid exposure included serious infections
(small increased risk in 1 study: 1.25; 95% CI, 1.0–
1.5)46 and cataracts (mean cumulative exposure
11.7 g, 0.9 [95% CI, 0.36–2.3]; mean cumulative ex-
posure 23.6 g, 2.5 [95%CI, 1.1–5.6]; and mean cumu-
lative exposure 60.6 g, 3.1 [95% CI, 1.3–7.5]).56
Other Key Findings By Tissue/Body System
Adrenal Effects
Hypothalamic-pituitary-adrenal suppression and
clinical sequelae (eg, thyroid dysfunction, sex hor-
11
Clinical TherapeuticsTable V. Risk for corticosteroid-associated adverse events (AEs) based on data from the published literature in
this analysis of the incidence and US costs of corticosteroid-associated AEs.*
AE
Risk Ratio
1–2
Risk Ratio
2–3
Risk Ratio
3–5
Risk Ratio
5
Any fracture X X X –
Back pain X – – –
Bacterial sepsis X – – –
Basal cell carcinoma X – – –
Bladder cancer X X – –
Bleeding X – – –
Bruising – – – X
Cataracts – X – X
Cushingoid phenotype† – – X X
Diabetes X –
Ecchymosis – – – X
Epistaxis – X – X
Gastric damage – X – –
Gastric lesions/ulcer‡ – X – X
GI hemorrhage X – – –
Height loss of2.5 cm X – – –
Hip/femur fracture§ X X X X
Hospitalization for atrial fibrillation
or flutter
X – X X
Hypertension X X – –
Hypokalemia X – – –
Infection X X – –
Leg edema X X – –
Lethal infection – X – X
Mental status change – – – X
Muscle weakness – – – X
Myocardial infarction X X – –
Non-Hodgkin’s lymphoma – X –
Nonlethal infections X X –
Oral candidiasis – – – X
Osteonecrosis of femoral head¶ – – X X
Parchmentlike skin – X X –
Peptic ulcer‡ X – – –
Ribs/sternum fracture – – X –
Sleep disturbance X X – –
Squamous cell carcinoma – – – X
Tuberculosis# X – – X
Ulcers – – X –
Upper GI complications X – – –
Upper limb fracture (not wrist) – X – –
Varicella infection – – – X
Vertebral fracture§ X X X X
Weight gain – X – –
GI  gastrointestinal.
*Only AEs with a statistically significant difference in risk between patients receiving corticosteroids and those not receiving corticosteroids are
listed. Some studies may have been underpowered to detect significant differences. The risk ratio could reflect a hazard ratio, an incidence risk
ratio, a relative risk, or an odds ratio.
†Risk for Cushingoid phenotype increased with higher corticosteroid dose.
‡Risk for gastrointestinal ulcers/lesions varied by study and appeared to increase with higher corticosteroid dose.
§Risk for vertebral fracture and hip/femur fracture increased with higher corticosteroid dose and in certain patient populations (eg, the elderly).
Risk for infection varied by type of infection and by study.
¶Risk for osteonecrosis of the femoral head varied by study and patient population.
#Risk for tuberculosis varied by study.12 Volume xx Number x
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high-dose corticosteroid therapy or therapy of long
duration. At daily doses 60 mg, the incidence of
adrenal suppression ranged from 34.6% to 87.5%
across studies.22,30,38
Bone Effects
Fractures were among the most frequently reported
AEs associated with corticosteroid use. The risk for
fracture varied by anatomic site. In general, the risk
ratio for any fracture in patients using systemic corti-
costeroids ranged from 1.60 to 1.75.19,56 The risk for
vertebral fracture with corticosteroid use was greater
than that for fractures at other sites—approximately
3-fold higher than in patients who did not use
corticosteroids.19,56
Cardiovascular Effects
Negative cardiovascular outcomes associated with
corticosteroid therapy included acute myocardial in-
farction, atrial fibrillation/flutter, hypertension, and
metabolic syndrome. Current users of corticosteroids
had a2-fold greater risk for atrial fibrillation or flut-
er compared with hospitalized patients who had never
eceived corticosteroids.15 The risk for acute myocar-
dial infarction was 40% to 60%higher in patients who
received corticosteroids than in patients who did not
receive corticosteroids (OR  1.4254 and 1.6011). The
isk for cardiovascular AEs appeared to decrease after
iscontinuation of corticosteroids. In 2 studies, the risk
atio for acute myocardial infarction and atrial fibril-
ation/flutter decreased as the time since last corticoste-
oid use increased.15,54 A relationship between corti-
costeroid daily dose and the incidence of acute
myocardial infarction was observed, with an estimated
risk ratio of 1.26 at daily doses 10 mg and 2.15 at
daily doses10mg.54 Corticosteroid-induced lipodys-
rophy, or redistribution of adipose tissue, was com-
only observed with long-term corticosteroid therapy.
n 2 prospective studies in the same group of 88 pa-
ients on long-term corticosteroid therapy at a daily
ose20 mg, the incidence of lipodystrophy exceeded
0%.23,24
Gastrointestinal Effects
Serious gastrointestinal events, including peptic ul-
cers, bleeding, and dyspepsia, were linked to the use of
oral and parenteral corticosteroids in several stud-
ies.25,29,35,42,44,46 However, reports regarding the risk
for peptic ulcers and gastrointestinal bleeding and cor-
Month 2011ticosteroid use were conflicting, with some studies re-
porting a strong association related to dose, and other
studies failing to find an association. Some evidence
suggests that the risk for gastric AEs associated with
corticosteroid use was increased by factors including
history of peptic ulcer disease, use of nonsteroidal anti-
inflammatory drugs/aspirin, advanced age, and vari-
ances in specific gastric enzymes.29,34,42,44
Hematologic/Oncologic Effects
The review byManson et al7 reported a relationship
between non-Hodgkin’s lymphoma and corticosteroid
use. In the 2 studies identified in the present analysis,
increased risks for basal cell carcinoma and bladder
cancer with corticosteroid use were documented.20,31
A significant association between oral corticosteroid
use and the risk for basal cell carcinoma was docu-
mented in a population-based case–control study from
Denmark (IRR 1.15).31 The risk for basal cell carci-
noma was increased slightly with duration of therapy,
from 1.17 with a duration of 1 year to 1.22 with a
duration of 5 years.31 In a population-based case–
ontrol study conducted in the United States, a signif-
cant increase in the incidence of bladder cancer was
ound in patients who reported taking oral corticoste-
oids for2 years (OR 1.87).20 The risk for bladder
ancer was increased 2-fold for patients taking cor-
icosteroids at the time of diagnosis (OR  2.18),
hereas a numeric but statistically nonsignificant in-
rease in risk was found among former users.20 Con-
clusions about these results should be made cautiously
given the small sample sizes and the multifactorial eti-
ology of cancer.
Infection
Corticosteroid use has been associated with tuber-
culosis, sepsis, pneumonia, bursitis, complicated uri-
nary tract infection, herpes zoster, varicella-zoster, and
fungal infections such as mycosis and oral candidiasis.
The risk for infection with corticosteroids appears to
be elevated with a daily dose 10 mg.‡ However, the
relative contributions of patients’ exposure to oral cor-
ticosteroids versus the underlying condition being
treated with corticosteroids to the increased risk for
infections are unclear. The underlying conditions or
concurrent use of immunosuppressive medications
may have contributed to the risk for infection.‡References 21, 22, 27, 30, 32, 41, 43, 46, and 50.
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Clinical TherapeuticsMetabolic Effects
Hyperglycemia and diabetes were frequently cited
as AEs of corticosteroid use, with frequencies up to
4-fold greater than those in controls.17,25,44,48 One
tudy that evaluated the dose-response relationship re-
orted that the incidence of weight gain was signifi-
antly increased with corticosteroid doses 5 mg/d
HR  2.4; P  0.004).30
Ocular Effects
The incidence of cataracts in corticosteroid users
was high (range, 7%–34%).25,30,37,44,46,56 The devel-
opment of cataracts with corticosteroid use was ob-
served at a low dose threshold (5 mg/d).
Psychiatric Effects
Mood changes, psychiatric disorders, and sleep distur-
bances were frequently reported with corticosteroid use,
although the cause-effect relationship was often un-
clear.12,14,24,30,39 The appearance of mania/hypomania
as reported after long-term treatment with high-dose
dose20mg/d for3months) and low-dose (7.5 mg/d
or 6 months) corticosteroids.24 Depression was re-
ported less often than mania or hypomania and was as-
sociated with long-term corticosteroid therapy at lower
doses.12–14
Cost Analysis
The costs of managing the AEs associated with cor-
ticosteroid use as identified from the published litera-
ture are shown inTable VI. Two recent publications7,8
evaluated the costs associated with corticosteroid-in-
duced AEs; the remaining publications evaluated the
costs of managing the AEs independent of association
with corticosteroids.60–69 Thus, the AEs were not nec-
ssarily attributed to corticosteroids in the studies
dentified. Costs per AE in the published literature were
dentified for bone, cardiovascular, metabolic, gastro-
ntestinal, ocular, psychiatric, and hematologic/onco-
ogic AEs, as well as for infections. The costs of frac-
ures, stroke, and gastrointestinal complications were
articularly high. The costs of managing specific AEs
ere substantial, with 1-year per-patient costs of up to
21,824.68 for peptic ulcer and $26,471.80 for non-
atal myocardial infarction and per-event costs of up to
18,357.90 for fracture.
Cost analyses to examine the potential reduction in
he economic burden of AEs achievable by reducing the
orticosteroid daily dose were conducted for myocar-
ial infarction and fracture—the AEs with the clearest d
14ose-response relationships identified in the literature
eview. Based on the risk for myocardial infarction in
he general population and the risks and incidences of
yocardial infarction associated with low and high
aily doses of corticosteroids, reducing the daily dose
f corticosteroids was estimated to avoid 19.4 myocar-
ial infarctions per 10,000 persons, for a cost reduc-
ion of $513,553 (2009 US dollars) per 10,000 persons
at $26,472 for the first-year cost of managing a myo-
ardial infarction62 Table VII). Given the range of
costs reported in the published literature, the same
analysis was conducted using the cost estimate of
$2942 per year reported by Manson et al.7 If this cost
ere applied, the potential cost avoidance would be
57,072 per 10,000 persons. Based on the risk for
racture in the elderly population and the risks and
ncidence of fracture associated with low and high
aily doses of corticosteroids, reducing the daily dose
f corticosteroids was estimated to avoid 96 fractures
er 10,000 persons, for a cost reduction of $1.76 mil-
ion per 10,000 persons. Similarly, if the cost estimate
f $14,064 per fracture from Manson et al7 were used
nstead, the potential cost avoidance would be $1.35
illion per 10,000 persons.
DISCUSSION
Corticosteroids are an integral aspect of management
of many autoimmune and inflammatory conditions.
Although corticosteroids have been reported to have
substantial clinical benefit in many diseases, they have
been associated with AEs, particularly with long-term
treatment. The findings from this review support that
systemic corticosteroids are a common cause of AEs.
AEs reported with particularly high frequency (30%
of patients) with corticosteroids included sleep distur-
bances, lipodystrophy, adrenal suppression, metabolic
syndrome, weight gain, and hypertension. AEs for
which patients who took corticosteroids were at sub-
stantially greater risk (3-fold) compared with those
n patients who did not take corticosteroids included
ruising, epistaxis, infections, oral candidiasis, squa-
ous cell carcinoma, muscle weakness, fractures,
trial fibrillation/flutter, Cushingoid phenotype, osteo-
ecrosis of the femoral head, parchmentlike skin, tu-
erculosis, and gastrointestinal ulcers.
These data should be interpreted cautiously. Con-
ucting systematic literature reviews on corticosteroid-
elated effects is challenging. Some studies did not ad-
ressed the potentially major impact of confounding
Volume xx Number x
E. Sarnes et al.Table VI. Costs per adverse event (AE) based on data from the published literature in this analysis of the
incidence and US costs of corticosteroid-associated AEs.
AE Cost, $
Cost/Episode/Year
(Inflated to 2009 US $)*
Skeletal
Any fracture
Pisu et al8 £6541.12 (cost per incident) 14,064.44
Schäcke et al57 8650.80 18,357.90
Vertebral fracture9 1500.00 (cost per incident) 1743.25
Hip fracture9 15,000.00 (cost per incident) 17432.5
Cardiovascular and metabolic
Diabetes
Pisu et al8 £2519.86 (cost/y) 5411.16
Hailey et al9 2900.00 (initial  6-mo) 3370.29
Metabolic syndrome58 4476.00 (cost/y) 5201.87
Myocardial infarction
Pisu et al8 £1369.95 (cost/y) 2941.84
American College of Rheumatology59 15,540 (first-year cost) 26,471.80
Stroke
Pisu et al8 £7148.33 (cost/y) 15,350.36
Hailey et al9 21,000.00 (hospitalization 
follow-up  rehabilitation)
24,405.55
Hypertension9 1300.00 (initial  6-mo) 1510.82
Immunologic
Gastroenteritis†60 6184.00 (per diem) 7818.21
Sepsis†60 7842.00 (per diem) 9914.36
Meningitis†60 10831.00 (per diem) 13,693.25
Tuberculosis, primary diagnosis†60 6118.00 (per diem) 7734.77
Pneumonia requiring hospitalization†60 4586.00 (per diem) 5797.92
Pneumonia, community-acquired9 1500.00 (per incident) 1743.25
Herpes zoster infection61 26,825.00 (per incident) 28,701.62
Varicella infection62 7993.00 (per incident) 10,512.17
Gastrointestinal
Peptic ulcer8 £10163.28 (cost/y) 21,824.68
GI complication9 39,400.00 (surgery,
hospitalization, outpatient care)
45,789.46
Ocular
Cataracts
Pisu et al8 £890.67 (cost/y) 1912.63
Hailey et al9 3800.00 (cataract surgery)† 4416.24
Hematologic/oncologic
Non-Hodgkin’s lymphoma8 £8210.21 (cost/y) 17,630.65
Psychiatric
Sleep disturbance (insomnia)63 4755.00 (6-mo costs) 6011.58
Depression64 3296.00 (cost/y) 4747.01
Depression, non–treatment-resistant65 1455.00 (cost/y) 1913.57
Psychosis‡66 3416.00 (cost/y) 5622.67
*Inflated to 2009 dollars using the medical Consumer Price Index (www.bls.gov); costs in British pounds converted to US $.
†Medical charges. Charges may overestimate the actual cost to the provider or system.
‡Costs reflect patients with severe mental illness.Month 2011 15
Clinical Therapeuticsby underlying disease activity. Furthermore, the in-
creased risk reported for systemic corticosteroid use is
not necessarily indicative of a high absolute incidence
of all of these AEs. For example, osteonecrosis of the
femoral head occurs with a low absolute incidence but
occurs more commonly in patients who took cortico-
steroids than in those who did not. In addition, the
types of AEs identified in the second literature search
conducted for this review might have been affected by
the search methodology, which involved searching for
specific AEs (eg, psychiatric/neurologic, peptic ulcer,
infection). The strategy of searching for specific AEs in
the second literature search might have resulted in fail-
ure to detect other corticosteroid-associated AEs.
However, the results were generally similar to those of
similar previous efforts.7,8 For example, in the study by
Manson et al,7 the most frequently reported corticoste-
roid-associated AE was fracture (28 studies), followed
by gastric conditions (13 studies) and psychiatric con-
ditions (11 studies). This pattern of results is similar to
that in the present analysis.
Several other limitations were derived from the
characteristics of the studies reviewed. Many of the
studies analyzed in the present review were not pro-
spectively designed to assess corticosteroid-associated
Table VII. Potential benefits associated with reducin
the general population and fracture in elde
this analysis of the incidence and US costs
Parameter
Risk in
General
Population,
%
Increased Risk with High-Dose
Corticosteroid
HR (95% CI) Incidenc
Myocardial
infarction in
general
population
0.22 2.15 (1.45–3.14)
(source: Varas-
Lorenzo et al
[2007]54; dose 10
mg/d)
0.47 (25 m
myocardia
infarctions
10,000 per
Any fracture
in elderly
patients
2.08 1.99 (1.82–2.16)
(source: de Vries et al
[2007]19; dose 7.5–
15 mg/d)
4.1 (414 m
fractures p
10,000 per
HR  hazard ratio.AEs. Accordingly, methodologies for assessing and re-
16porting AEs were inconsistent across studies. Most of
the studies were retrospective and had small sample
sizes. Most of the studies had other weaknesses that
might have limited the generalizability of the results as
evidenced by the quality assessment. Many of the stud-
ies identified in the review evaluated only a single AE or
type of AE. Most of the studies included all corticoste-
roid users; therefore, it was not possible to evaluate
trends by specific corticosteroid therapy or in specific
patient populations. Because the evidence base for
some of the AEs, such as hematologic/oncologic
events, was relatively small, some general trends could
not be discerned. Because of the generally poor quality
of many of the studies and the heterogeneity in study
designs and populations, any trends or patterns should
be interpreted cautiously.
The incidence of many AEs (eg, fracture, acute myo-
cardial infarction, weight gain, infections, psychiatric
events) was directly related to daily corticosteroid
dose. These dose-response relationships were manifest
despite substantial variability across studies in study
design, population, daily dose, conditions treated, and
treatment duration. The dose-response pattern in-
cluded threshold effects. Other corticosteroid-associ-
ated AEs also appeared to occur with an incidence di-
daily corticosteroid dose for myocardial infarction in
tients, based on data from the published literature in
rticosteroid-associated adverse events.
Increased Risk with Low-Dose
Corticosteroid
Potential Benefits of
Reducing Daily
Dose
HR (95% CI) Incidence, %
1.26 (1.02–1.57)
(source: Varas-
Lorenzo et al
[2007]54; dose 10
mg/d)
0.27 (5.6
more
myocardial
infarctions per
10,000
persons)
Avoidance of 19.4
myocardial
infarctions per
10,000 persons;
cost reduction of
$513,553 per
10,000 persons
1.53 (1.43–1.63)
(source: de Vries et al
[2007]19; dose 7.5
mg/d)
3.2 (318 more
fractures per
10,000
persons)
Avoidance of 96
fractures per 10,000
persons; cost
reduction of $1.76
million per 10,000
personsg the
rly pa
of co
e, %
ore
l
per
sons)
ore
er
sons)rectly related to daily dose; however, trends appeared
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E. Sarnes et al.to be less robust. In many cases, the inability to discern
a definitive trend was related to a small number of
studies or reports, lack of information on risk ratios,
conflicting study results, and heterogeneity of patient
populations. In addition to dose, certain AEs appeared
to have been associated with cumulative corticosteroid
exposure. Fractures, serious infections, and cataracts
were all reported to be significantly associated with
cumulative dose. Conclusions regarding cumulative
exposure were limited, however, as few studies directly
reported on these associations. Attempts to determine
cumulative doses to draw further conclusions were un-
successful because most studies did not provide suffi-
cient details to calculate the dose.
Little information on the cost of AEs directly asso-
ciated with corticosteroids was identified in the pub-
lished literature. Previous economic analyses reported
that the incremental cost of corticosteroid-induced
AEs was $344 per patient per year (inflated to 2009 US
dollars),7 or $540 per patient per 2-year period.8 These
costs took some, but not all, of the potential AEs into
consideration, excluding psychiatric events, rare but
costly events (eg, avascular necrosis of the femoral
head), and other AEs identified in the literature search.
The lack of information may be attributed in part to
the difficulty in conducting cost research on AEs. Chal-
lenges of such research include those of identifying
drug-attributable AEs with certainty, determining
costs directly attributable to the AE (vs other opera-
tives, eg, underlying disease), and the need to rely on
retrospective analyses of data collected for reasons
other than assessing AE costs. The limited information
available does not allow for broad conclusions about
the costs of corticosteroid-associated AEs. However,
based on the findings from the literature, the costs of
events that may occur with corticosteroids is high. For
example, the 1-year per-patient cost of myocardial in-
farction was reported to be as high as $26,472; this
cost would be incurred by the health care system re-
gardless of the cause of the infarction. Similarly, the
costs of peptic ulcer and fractures are significant at
1-year per-patient costs of up to $21,825 for peptic
ulcer and up to $18,358 per fracture event. However, a
comprehensive pharmacoeconomic analysis should be
undertaken to confirm the findings of this preliminary
cost analysis. Given the number of patients using long-
term corticosteroids, the cumulative costs for a health
plan could be substantial. Reducing the daily cortico-
steroid dose requirements may reduce the incidence of
Month 2011certain AEs, such as fracture and acute myocardial in-
farction, and thereby reduce the costs associated with
corticosteroid therapy.
CONCLUSIONS
Based on findings from this literature review, systemic
corticosteroids are a common cause of AEs that range
from bothersome to patients to severe or life-threaten-
ing. Corticosteroid-induced AEs such as sleep distur-
bances, lipodystrophy, hypertension, and adrenal sup-
pression were reported with high frequency; while the
absolute incidence was low for other AEs (eg, acute
myocardial infarction and infections), corticosteroids
were still significantly associated with a greater risk of
development. The risk of developing AEs increased
with higher corticosteroid dose for fractures, hyperten-
sion, acute myocardial infarction, and peptic ulcer.
The costs of these AEsmay be substantial to payers and
far greater than the product costs of the corticosteroid.
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